Mosaic ImmunoEngineering Inc.
For the period ended Sep 30, 2025. Filed Nov 19, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | Other Information |
|---|
Mr. Lytle resigned as EVP, Chief Financial Officer and from the Board of Directors of the Company on August 15, 2025. Mr. Lytle’s resignation was not the result of any disagreement with either the Board of Directors or management of the Company. Mr. Steven King, President and CEO, assumed the role of Principal Financial Officer and Principal Accounting Officer.
Dr. Garnick resigned from the Board of Directors of the Company and any committees of the Board of Directors effective August 15, 2025. The resignation was not the result of any disagreement with either the Board of Directors or management of the Company.
Dr. Baffi resigned from the Board of Directors of the Company and any committees of the Board of Directors effective August 18, 2025. The resignation was not the result of any disagreement with either the Board of Directors or management of the Company.
During the quarter ended September 30, 2025, no director or officer adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.